Medpace (NASDAQ:MEDP) Upgraded at Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of Medpace (NASDAQ:MEDP) to a moderate buy rating in a report issued on Monday,Zacks.com reports.

Several other research analysts have also recently weighed in on the company. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. BMO Capital Markets reissued a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and lowered their target price for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Five analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $486.67.

Medpace Stock Performance

Shares of MEDP stock opened at $465.86 on Monday. The company has a market capitalization of $13.22 billion, a price-to-earnings ratio of 30.45, a price-to-earnings-growth ratio of 2.23 and a beta of 1.44. Medpace has a one year low of $250.05 and a one year high of $628.92. The company’s 50-day moving average is $537.93 and its 200 day moving average is $538.85.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same quarter last year, the firm earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts predict that Medpace will post 12.29 earnings per share for the current fiscal year.

Institutional Trading of Medpace

A number of hedge funds have recently modified their holdings of MEDP. AQR Capital Management LLC lifted its holdings in Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after acquiring an additional 404,226 shares during the period. Norges Bank purchased a new position in Medpace in the 2nd quarter valued at about $66,597,000. Arrowstreet Capital Limited Partnership boosted its stake in shares of Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after acquiring an additional 211,411 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Medpace by 158.6% during the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after buying an additional 183,645 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Medpace by 92.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock valued at $194,920,000 after acquiring an additional 166,654 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.